$150,000 of HARMONY BIOSCIENCES lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"HR 946/ S 1862 ORPHAN Cures Act S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act"
You can find more data on corporate lobbying on Quiver Quantitative.
HRMY Insider Trading Activity
HRMY insiders have traded $HRMY stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $HRMY stock by insiders over the last 6 months:
- SANDIP KAPADIA (CHIEF FINANCIAL OFFICER) has made 0 purchases and 2 sales selling 26,775 shares for an estimated $1,072,144.
- JEFFREY M. DAYNO (PRESIDENT, CEO) sold 19,293 shares for an estimated $774,245
- JEFFREY DIERKS (CHIEF COMMERCIAL OFFICER) has made 0 purchases and 4 sales selling 15,877 shares for an estimated $596,495.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HRMY Hedge Fund Activity
We have seen 131 institutional investors add shares of HRMY stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PACER ADVISORS, INC. removed 1,782,959 shares (-78.2%) from their portfolio in Q1 2025, for an estimated $59,176,409
- DEEP TRACK CAPITAL, LP removed 1,450,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $48,125,500
- CITADEL ADVISORS LLC removed 505,826 shares (-37.0%) from their portfolio in Q1 2025, for an estimated $16,788,364
- NEW VERNON CAPITAL HOLDINGS II LLC added 473,708 shares (+3219.0%) to their portfolio in Q1 2025, for an estimated $15,722,368
- BLACKROCK, INC. removed 456,224 shares (-6.5%) from their portfolio in Q1 2025, for an estimated $15,142,074
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 332,000 shares (-66.4%) from their portfolio in Q1 2025, for an estimated $11,019,080
- CAMBRIA INVESTMENT MANAGEMENT, L.P. removed 310,908 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $10,319,036
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HRMY Analyst Ratings
Wall Street analysts have issued reports on $HRMY in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Deutsche Bank issued a "Buy" rating on 07/10/2025
- Oppenheimer issued a "Outperform" rating on 06/02/2025
- Mizuho issued a "Outperform" rating on 05/15/2025
- Needham issued a "Buy" rating on 05/07/2025
- UBS issued a "Buy" rating on 04/28/2025
- HC Wainwright & Co. issued a "Buy" rating on 04/08/2025
To track analyst ratings and price targets for HRMY, check out Quiver Quantitative's $HRMY forecast page.
HRMY Price Targets
Multiple analysts have issued price targets for $HRMY recently. We have seen 7 analysts offer price targets for $HRMY in the last 6 months, with a median target of $49.0.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $48.0 on 07/21/2025
- David Hoang from Deutsche Bank set a target price of $55.0 on 07/10/2025
- Andreas Argyrides from Oppenheimer set a target price of $61.0 on 06/02/2025
- Graig Suvannavejh from Mizuho set a target price of $48.0 on 05/15/2025
- Ami Fadia from Needham set a target price of $49.0 on 05/07/2025
- Ashwani Verma from UBS set a target price of $48.0 on 04/28/2025
- Patrick Trucchio from HC Wainwright & Co. set a target price of $70.0 on 04/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
